![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » NICE Recommends Against Roche’s Tecentriq for Triple-Negative Breast Cancer
NICE Recommends Against Roche’s Tecentriq for Triple-Negative Breast Cancer
October 16, 2019
The UK’s National Institute for Health and Care Excellence recommended against Roche’s Tecentriq (atezolizumab) injection for triple-negative breast cancer for coverage through the National Health Service.
In a draft recommendation, NICE found that atezolizumab with the chemotherapy drug Abraxane (nab-paclitaxel) is unlikely to be cost-effective and there is no clear evidence that further data would resolve the uncertainties.
The agency also found that the evidence suggesting Tecentriq plus nab-paclitaxel extends the time before the disease worsens by 2.5 months compared to placebo plus nab-paclitaxel is “unreliable.”
Upcoming Events
-
21Oct